Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NIMBC and Quantifies Molecular Response to Nadofaragene Firadenovec – Vikram Narayan
Sam Chang hosts Vikram Narayan for a discussion on the potential of urinary markers in predicting responses to nadofaragene, a treatment for BCG-unresponsive bladder cancer. Dr. Narayan discusses findings from a study utilizing the UroAmp test for assessing urinary minimal residual disease (MRD) in patients treated with nadofaragene. This next-generation sequencing approach reveals the mutation…